Thanks for the links, interesting data. As a representative of the “average retail investor” (tuulipukusijoittaja), I really have to wonder about the company’s investor communications. WISER’s materials already contain quite concrete signs of the progress of the China venture, which Optomed itself has said very little about.
According to WISER, Optomed’s Aurora camera has NMPA approval in China. In addition, screening pilots have been launched in China, partnerships have been built with a hospital and a local AI operator, and a partnership has been established with a long-standing large optician chain. Now, Optomed’s Chinese joint venture is looking for someone to build sales for, among other things, clinics, optician shops, insurance companies, and the public sector.
If this is the path forward, then admittedly this is starting to form an interesting scenario for an investor. The regulation seems to be in order, local partners are in place, and commercial channels are being built. The Chinese model also appears broader than the U.S. model. Alongside diabetes screening, myopia as well as optician shops and primary healthcare are included. Not to mention that there are over 230 million diabetics and over 130 million people suffering from high-degree myopia in China, so the potential market is enormous.
WISER’s material is marketing-oriented, and of course, approvals, pilots, or partnerships do not yet tell us about the revenue generated for Optomed. The real value of the China case will only be determined when this activity turns into commercial volumes.
But back to investor communications. Both named partnerships started in June, i.e., in the same quarter that the August Q2 report covered. Still, it was difficult to conclude from the report that such an active commercial entity is being built in China. It is somewhat incomprehensible that those who have invested in Optomed have to piece together this kind of picture from Chinese sources. A sincere tip of the hat to the folks on the forum for their detective work.
It is also a pity that this wasn’t asked about in the CEO interview. China now looks clearly more interesting than Optomed’s own communications let on. It leaves one wondering, when will all this start to show up in Optomed’s revenue and cash flow?